CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
Donepezil Hydrochloride +1 moredrug
Likely dose
Donepezil Hydrochloride 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01260948
NCT01260948Phase 1Completed
CompareCT.gov

A Relative Bioavailability Study of 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions.

Teva Pharmaceuticals USA·interventional·Posted Dec 15, 2010·Updated Feb 21, 2011

In Brief

A Phase 1 clinical trial evaluating Donepezil Hydrochloride and Aricept® for Healthy. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This study investigated the relative bioavailability (rate and extend of absorption) of Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc., following a single oral dose (1 x 10 mg orally disintegrating tablet) in healthy adult subjects administered under non-fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 15, 2010
Enrollment StartApr 1, 2006
Primary CompletionMay 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.5 years ago

Interventions

Donepezil Hydrochloridedrug

10 mg Orally Disintegrating Tablet

Aricept®drug

10 mg Orally Disintegrating Tablet